Table 1.
Clinico-pathological characteristics of the 114 patients with primary cutaneous melanoma.
| Characteristic | Group | N (%) |
|---|---|---|
| Sex | Male | 69 (60.5%) |
| Female | 45 (39.5%) | |
| Age range: 24–93 | ≤66 | 58 (50.9%) |
| (mean/median = 62/66 years) | >66 | 56 (49.1%) |
| Classification (tumor stage) | pT1 (≤1 mm) | 5 (4.4%) |
| pT2 (>1–2 mm) | 23 (20.2%) | |
| pT3 (>2–4 mm) | 48 (42.1%) | |
| pT4 (>4 mm) | 38 (33.3%) | |
| Location | Head | 10 (8.8%) |
| Trunk | 69 (60.5%) | |
| Upper extremities | 17 (14.9%) | |
| Lower extremities | 18 (15.8%) | |
| Histological subtype | SSM | 68 (59.6%) |
| NM | 46 (40.4%) | |
| Ulceration | No | 60 (52.6%) |
| Yes | 54 (47.4%) | |
| Regression | No | 93 (81.6%) |
| Yes | 21 (18.4%) | |
| Sentinel nodes | No | 43 (37.7%) |
| Yes | 71 (62.3%) - 19 positive (26.7%) | |
| TILs† | Absent | 7 (9.5%) |
| (scoring system by Clark) | Non-brisk | 50 (67.5%) |
| Brisk | 17 (23.0%) | |
| Death due to melanoma‡ | No | 71 (67.6%) |
| §mean/median DFS = 34/24 months | Yes | 34 (32.4%) |
| Local recurrence‡ | No | 88 (83.8%) |
| §mean/median LFS = 22/10 months | Yes | 17 (16.2%) |
| Metastasis‡ | No | 81 (77.1%) |
| §mean/median MFS = 25/18 months | Yes | 24 (22.9%) |
†Information is missing for several cases, ‡data is based on 105 cases without targeted therapy. §Mean and median of months was calculated only for cases with respective events. DFS – disease-free survival, LFS – local recurrence-free survival, MFS – metastasis-free survival, NM – nodular melanoma, SSM - superficial spreading melanoma, TIL – tumor infiltrating lymphocytes. TILs were assessed using the scoring system by Clark as described elsewhere46.